SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001610618-24-000088
Filing Date
2024-06-03
Accepted
2024-06-03 16:38:12
Documents
5

Document Format Files

Seq Description Document Type Size
1 DEFINITIVE ADDITIONAL MATERIALS cdtxdefa14a2024.htm DEFA14A 13898
2 cdtx_noticexpagex1.jpg GRAPHIC 3116818
3 cdtx_noticexpagex2.jpg GRAPHIC 4933054
4 cdtx_noticexpagex3.jpg GRAPHIC 3116712
5 cdtx_noticexpagex4.jpg GRAPHIC 4141640
  Complete submission text file 0001610618-24-000088.txt   21068731
Mailing Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121
Business Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 858-752-6170
Cidara Therapeutics, Inc. (Filer) CIK: 0001610618 (see all company filings)

IRS No.: 461537286 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-36912 | Film No.: 241014279
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)